The OPUS (Oral Peptide Utility System) is our technology application to orally (sublingually) or via the mucosum administer peptides which have no immunomodulatory mode of action. Our lead product is an oral GLP-1 molecule for treatment of diabetes type II, and potentially obesity and "pre-diabetes".
The figure below demonstrates that the sublingual formulation (SL) (Group 3) can very closely match the profile of subcutaneous (SC) (group 4) exenatide.
Figure : Pharmacodynamic effect of exenatide on blood-glucose as compared between sublingual and subcutaneous administration (IPTG experiment in DIO mice).
What is important to note is the very low variability of the sublingually administered exenatide. It is not substantially higher than the subcutaneuously administered exenatide. High variability is probably one of the key reasons why orally administered insulin has failed in the past. There are several potential applications of the OPUS technology in Diabetes, but also other disease areas.
Another example of an application of the OPUS technology is the development of a unique "Insulin Plus" formulation
BioLingus sublingual "Insulin Plus" (sublingual Novolog formulation) mirrors the effect of 1IU SC Novolog
Our oral formulation mitigates the risk of unacceptable variations in insulin, which could be expected in an oral formulation